Cláudia S. Rodrigues

Ms. Cláudia S. Rodrigues

University of Lisbon, Lisbon, Lisboa, Portugal
+1
orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
IPInes Pankonien
Ines Pankonien
MQMargarida Quaresma
Margarida Quaresma
Cláudia S. RodriguesCláudia S. Rodrigues
Cláudia S. Rodrigues
MAMargarida Amaral
Margarida Amaral
The multi-organ disease cystic fibrosis (CF) is caused by mutations in the gene encoding the CF transmembrane conductance regulator (CFTR) protein, a cAMP regulated chloride (Cl−) and bicarbonate (HCO3−) ion channel expressed at the apical plasma membrane (PM) of epithelial cells. Reduced CFTR protein results in decreased Cl− secretion and excessive sodium reabsorption in epithelial cells, which consequently leads to epithelial dehydration and the accumulation of thick mucus within the affected organs, such as the lungs, pancreas, gastrointestinal (GI) tract, reproductive system and sweat glands. However, CFTR has been implicated in other functions besides transporting ions across epithelia. The rising number of references concerning its association to actin cytoskeleton organization, epithelial cell junctions and extracellular matrix (ECM) proteins suggests a role in the formation and maintenance of epithelial apical basolateral polarity. This review will focus on recent literature (the last 10 years) substantiating the role of CFTR in cell junction formation and actin cytoskeleton organization with its connection to the ECM.

2 May 2022 in Life Science Alliance
Verified
Journal Article
Open access
PDF file
MQMargarida C Quaresma
Margarida C Quaresma
HBHugo M Botelho
Hugo M Botelho
IPInes Pankonien
Ines Pankonien
Cláudia S. RodriguesCláudia S. Rodrigues
Cláudia S. Rodrigues
MPMadalena Pinto
Madalena Pinto
MAMargarida Amaral
Margarida Amaral
Mutations in the CFTR anion channel cause cystic fibrosis (CF) and have also been related to higher cancer incidence. Previously we proposed that this is linked to an emerging role of functional CFTR in protecting against epithelial–mesenchymal transition (EMT). However, the pathways bridging dysfunctional CFTR to EMT remain elusive. Here, we applied systems biology to address this question. Our data show that YAP1 is aberrantly active in the presence of mutant CFTR, interacting with F508del, but not with wt-CFTR, and that YAP1 knockdown rescues F508del-CFTR processing and function. Subsequent analysis of YAP1 interactors and roles in cells expressing either wt- or F508del-CFTR reveal that YAP1 is an important mediator of the fibrotic/EMT processes in CF. Alongside, five main pathways emerge here as key in linking mutant CFTR to EMT, namely, (1) the Hippo pathway; (2) the Wnt pathway; (3) the TGFβ pathway; (4) the p53 pathway; and (5) MYC signaling. Several potential hub proteins which mediate the crosstalk among these pathways were also identified, appearing as potential therapeutic targets for both CF and cancer.

6 February 2025 in Journal of Cystic Fibrosis
Verified
Journal Article
Open access
Cláudia S. RodriguesCláudia S. Rodrigues
Cláudia S. Rodrigues
VRVioleta Railean
Violeta Railean
SRSofia S Ramalho
Sofia S Ramalho
Carlos FarinhaCarlos Farinha
Carlos Farinha
IPInes Pankonien
Ines Pankonien
MAMargarida Amaral
Margarida Amaral
Elucidating the molecular and cellular effects caused by CFTR variants is crucial to understand Cystic Fibrosis (CF) disease pathophysiology, but also to predict disease severity, to provide genetic counselling, and to determine the most adequate therapeutic strategy for people with CF (pwCF). While the current CFTR modulator drugs (CFTRm) are approved mainly for pwCF with the most prevalent variant, p.Phe508del, pwCF carrying rare and/or uncharacterized CFTR variants are not eligible. However, previous studies have shown that such rare variants can be rescued by the approved CFTRm, suggesting clinical benefit for those pwCF. Here, we characterized the rare and non-eligible p.Ile148Asn CFTR variant found in Portuguese pwCF, regarding CFTR processing, traffic and function, and response to existing CFTRm. We used the forskolin-induced swelling (FIS) assay in intestinal organoids (IOs) from 2 CF individuals carrying p.Ile148Asn in heterozygosity with p.Phe508del and p.Gly542Ter, respectively. Additionally, a Cystic Fibrosis Bronchial Epithelial (CFBE) cell line expressing p.Ile148Asn-CFTR was generated to study the molecular defect of this variant individually. Our results show that p.Ile148Asn is a CF-causing variant, impairing both CFTR plasma membrane (PM) traffic and function, albeit partially. Moreover, p.Ile148Asn-CFTR can be rescued by approved CFTRm in CFBE cells and IOs, suggesting potential clinical benefit for these individuals. The work emphasizes the importance of testing CFTRm for rare variants not included in the drug label. It also shows that the 'theranostic' approach using IOs from pwCF, which captures the genetic background of each individual, complements theratyping in cell lines that focuses only on CFTR variants.

15 July 2025 in Respiratory Medicine
Verified
Journal Article
Closed access
JPJoana Pacheco
Joana Pacheco
LALeonor Almeida
Leonor Almeida
RBRita Boaventura
Rita Boaventura
APAna Luisa Pereira
Ana Luisa Pereira
Cláudia S. RodriguesCláudia S. Rodrigues
Cláudia S. Rodrigues
AAAdelina Amorim
Adelina Amorim